Your browser doesn't support javascript.
loading
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno, Adrián; Palomeras, Sonia; Pedersen, Kim; Morancho, Beatriz; Pascual, Tomas; Galván, Patricia; Benítez, Sandra; Gomez-Miragaya, Jorge; Ciscar, Marina; Jimenez, Maria; Pernas, Sonia; Petit, Anna; Soler-Monsó, María Teresa; Viñas, Gemma; Alsaleem, Mansour; Rakha, Emad A; Green, Andrew R; Santamaria, Patricia G; Mulder, Celine; Lemeer, Simone; Arribas, Joaquin; Prat, Aleix; Puig, Teresa; Gonzalez-Suarez, Eva.
Afiliación
  • Sanz-Moreno A; Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Palomeras S; Present Address: German Mouse Clinic, Institute of Experimental Genetics, HMGU, Neuherberg, 85764, Germany.
  • Pedersen K; New Therapeutics Targets Lab (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain.
  • Morancho B; Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Pascual T; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Galván P; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Benítez S; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Gomez-Miragaya J; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Ciscar M; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
  • Jimenez M; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Pernas S; Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Petit A; Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Soler-Monsó MT; Present Address: Department of Biomedicine, Department of Surgery, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Viñas G; Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Alsaleem M; Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Rakha EA; Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Green AR; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Santamaria PG; Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology (ICO), University Hospital of Bellvitge IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Mulder C; Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology (ICO), University Hospital of Bellvitge IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Lemeer S; Pathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.
  • Arribas J; Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology (ICO), University Hospital of Bellvitge IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Prat A; Pathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.
  • Puig T; New Therapeutics Targets Lab (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain.
  • Gonzalez-Suarez E; Medical Oncology Department, Catalan Institute of Oncology (ICO), Girona, Spain.
Breast Cancer Res ; 23(1): 42, 2021 03 30.
Article en En | MEDLINE | ID: mdl-33785053
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Resistencia a Antineoplásicos / Receptor Activador del Factor Nuclear kappa-B Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Resistencia a Antineoplásicos / Receptor Activador del Factor Nuclear kappa-B Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: España